These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35884359)

  • 1. Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study.
    Meleshko A; Piatrouskaya N; Vashkevich K; Lutskovich D; Wang C; Dormeshkin D; Savelyeva N; Katsin M
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.
    Meleshko AN; Petrovskaya NA; Savelyeva N; Vashkevich KP; Doronina SN; Sachivko NV
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-6. PubMed ID: 28272989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
    Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
    Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
    Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
    Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
    Schmitz-Winnenthal FH; Hohmann N; Schmidt T; Podola L; Friedrich T; Lubenau H; Springer M; Wieckowski S; Breiner KM; Mikus G; Büchler MW; Keller AV; Koc R; Springfeld C; Knebel P; Bucur M; Grenacher L; Haefeli WE; Beckhove P
    Oncoimmunology; 2018; 7(4):e1303584. PubMed ID: 29632710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
    Koumarianou A; Kountourakis P; Economopoulos T
    J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):230-2. PubMed ID: 18406604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugation of new DNA vaccine with polyethylenimine induces cellular immune response and tumor regression in neuroblastoma mouse model.
    Stegantseva MV; Shinkevich VA; Tumar EM; Meleshko AN
    Exp Oncol; 2020 Jun; 42(2):120-125. PubMed ID: 32602294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
    J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetic approach to idiotypic vaccination for B cell lymphoma.
    Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
    Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.